产品说明书

D-(+)-Cycloserine

Print
Chemical Structure| 68-41-7 同义名 : D-环丝氨酸 ;α-Cycloserine;RO-1-9213;Oxamycin;Orientomycin;68-41-7;Seromycin;Cycloserine;NSC 154851;NSC 76029;(R)-Cycloserine;(+)-Cycloserine;D-Cycloserine
CAS号 : 68-41-7
货号 : A170761
分子式 : C3H6N2O2
纯度 : 98%
分子量 : 102.092
MDL号 : MFCD00005353
存储条件：

粉末 Keep in dark place,Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 1 mg/mL(9.8 mM)，配合水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 25 mg/mL(244.88 mM)，配合低频超声助溶
动物实验配方：
生物活性
描述 D-cycloserine is an antibiotic which targets sequential bacterial cell wall peptidoglycan biosynthesis enzymes: alanine racemase and D-alanine:D-alanine ligase[3]. Furthermore, in an in vivo infection model with silkworms, combined treatment with vancomycin and D-cycloserine exhibited therapeutic effects, whereas treatment with each compound alone did not. These findings suggest that combined treatment with vancomycin and D-cycloserine could be therapeutically effective against infectious diseases caused by VRSA (vancomycin-highly resistant S. aureus)[4]. D-cycloserine is used to treat multidrug-resistant tuberculosis. Cyloserine killed 6.3 log10 colony-forming units (CFU)/mL extracellular bacilli over 28 days[5]. D-Cycloserine (CYC), a partial N-methyl-D-aspartate (NMDA) agonist, has been shown to improve cognitive functions in humans. D-CYC alone did not modulate excitability. The potency of this drug to consolidate neuronal excitability enhancements, most probably by stabilizing the strengthening of NMDA receptors[6]. D-Cycloserine in low-dose therapy is safe, but there is still a need for new drugs with higher specificity to the different N-methyl-D-aspartate-receptor subunits[7].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

9.80mL

1.96mL

0.98mL

48.98mL

9.80mL

4.90mL

97.95mL

19.59mL

9.80mL
参考文献

[1]Parnas AS, Weber M, Richardson R. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem. 2005 May;83(3):224-31.

[2]Flood JF, Morley JE, Lanthorn TH. Effect on memory processing by D-cycloserine, an agonist of the NMDA/glycine receptor. Eur J Pharmacol. 1992 Oct 20;221(2-3):249-54.

[3]Batson S, de Chiara C, Majce V, et al. Inhibition of D-Ala:D-Ala ligase through a phosphorylated form of the antibiotic D-cycloserine. Nat Commun. 2017;8(1):1939.

[4]Tabuchi F, Matsumoto Y, Ishii M, et al. D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus. J Antibiot (Tokyo). 2017;70(8):907–910

[5]Deshpande D, Alffenaar JC, Köser CU, et al. d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. Clin Infect Dis. 2018;67(suppl_3):S308–S316

[6]Nitsche MA, Jaussi W, Liebetanz D, Lang N, Tergau F, Paulus W. Consolidation of human motor cortical neuroplasticity by D-cycloserine. Neuropsychopharmacology. 2004;29(8):1573–1578

[7]Schade S, Paulus W. D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review. Int J Neuropsychopharmacol. 2016;19(4):pyv102.